Eli Lilly Bolsters Genetic Medicine Pipeline With $3.2 Billion Kelonia Therapeutics Acquisition INDIANAPOLIS — In a decisive move to dominate the next frontier of oncology, Eli Lilly has announced the acquisition of Kelonia Therapeutics for $3.2 billion, signaling a massive bet on the future of internal genetic reprogramming. The deal secures a promising in vivo … Read more
The landscape of multiple myeloma treatment is shifting, and new data from the MajesTEC-1 study offers crucial insights into managing the side effects of teclistamab, a promising new therapy. While the drug demonstrates significant efficacy – improving myeloma in 63% of participants – proactive management of Cytokine Release Syndrome (CRS) and infections is paramount for … Read more
The Dawn of Functional Cures: How Epstein-Barr Virus Research is Redefining Cancer Treatment Nearly 95% of the global population carries the Epstein-Barr virus (EBV), often without knowing it. For most, it’s a harmless childhood infection. But for a significant minority, EBV is a lifelong threat, linked to a spectrum of cancers, including the aggressive follicular … Read more
The Evolving Plate: How Personalized Nutrition Will Rewrite Cancer Risk in the Age of Plant-Based Diets Nearly 40% of individuals diagnosed with colorectal cancer who adhere to primarily plant-based diets report a surprising link to increased risk. This isn’t a condemnation of vegetarianism or veganism, but a stark signal: the future of dietary health isn’t … Read more
Multiple Myeloma: Advances in Treatment Offer Hope for Extended Lifespans Recent breakthroughs in the understanding and treatment of multiple myeloma are significantly improving patient outcomes, offering longer lives and enhanced quality of life. From innovative therapies like CAR-T cell therapy to targeted agents like belantamab mafodotin, the landscape of myeloma treatment is rapidly evolving. Understanding … Read more
The landscape of multiple myeloma treatment is poised for a significant shift as new research illuminates stark sex-based differences in how the disease manifests and progresses. For years, clinicians have observed variations in outcomes between men and women with this blood cancer, but the underlying reasons remained elusive. A comprehensive new study from the University … Read more